The stock of Pfizer Inc. (NYSE:PFE) decreased by -$0.17 on Monday to finish at $36.21, down -0.47 percent. The last five days have seen an average of 17,762,320 shares of common stock traded. 2 times new highs were reached in the current year, with a fall of -$15.03. The average number of shares traded over the last 20 days was 23,565,945, while the average volume over the last 50 days totaled 24,710,260.
PFE stock appreciated 0.39% since last month. On 08/04/23, the company’s shares reached a one-month low of $34.65. The stock touched a high of $54.93 on 01/06/23, after rallying from a low of $34.65 in 52 weeks. The price of PFE stock has declined by -29.33% or -$15.03 this year, reaching a new high 2 times. Still, the stock price is down -34.08% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
PFE stock investors should be aware that Pfizer Inc. (PFE) stock had its last reported insider trading activity 113 days ago on May 08. On May 08, Director Gottlieb Scott acquired 1,000 shares at $38.58 each. This transaction resulted in the insider spending $38,580. On May 05, Gottlieb Scott added 1,000 shares at a price of US$38.42. After the transaction, the insider now owns 5,000 shares. 10% Owner PFIZER INC had earlier bought 1,811,594 shares on Mar 17 for $2.76 a share. The transaction was completed for $4,999,999.
Valuation Metrics
Pfizer Inc. (PFE) has a trailing price-to-earnings (P/E) ratio of 9.65. Beta for the stock is 0.57. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 2.61, the price-to-book (PB) ratio of 2.06, and the price-to-cash flow ratio of 19.06.
Company paid $0.41 per share in dividends, remained unchanged from $0.41 last year. A $0.01 dividend increase was reported on Friday December 9 2022.
Financial Health
For the three months ended June 29, Pfizer Inc.’s quick ratio was 1.80, while its current ratio was 2.10, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 0.62, and the total debt to equity ratio is 0.66. As far as profitability goes, gross margin for the trailing twelve months is 68.80% percent. Pfizer Inc.’s EBITDA margin for the year ended June 29 was 42.47%, whereas its operating margin stood at 29.90% for the same period. Based on annual data, it had gross profit of $65.99 billion and revenue of $100.33 billion.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. PFE’s return on assets (ROA) during the last 12 months has been 10.60%. There was a 25.30% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 22.10%.
Earnings Surprise
According to Pfizer Inc.’s quarterly financial report for the quarter that ended June 29. A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $12.73 billion, while revenues fell by -117.86% to $18.28 billion. It was predicted that Pfizer Inc.’s quarterly earnings would be $0.62, but it ended up being $0.53, beating the consensus by 17.00%. EBITDA was $3.49 billion for the quarter. At the end of Pfizer Inc.’s most recent quarter ended June 29, its liabilities totaled 120.88 billion, while its total debt was $65.67 billion. Equity owned by shareholders amounts to $5.65 billion.
Technical Picture
Here’s a quick look at Pfizer Inc.’s (PFE) price momentum from a technical perspective. As of 28 August, the RSI 9-day stood at 49.09%, suggesting the stock is Neutral, with a 17.95% historical volatility rate.
The stochastic %K and %D were 57.93% and 65.78% respectively, while the average true range (ATR) was 0.71. Based on the 14-day stochastic reading of 55.45%, the RSI (14) reading is 48.96%. On the 9-day MACD Oscillator, the stock is at -0.18, and the 14-day reading is at 0.04.
Analyst Ratings
In a note to investors, JP Morgan maintained its a Neutral rating on Pfizer Inc. (NYSE: PFE). However, the firm raised their price target to $41, indicating a possible increase of 19.53% in the stock price. Analysts have assigned Pfizer Inc. (PFE) an Overweight rating. PFE is a stock that is recommended for selling by 0 brokerage firms, while 16 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 2 rates it overweight and 9 others recommend it as a buy.
What is PFE’s price target for the next 12 months?
The current consensus forecast for the stock is between $32.00 and $75.00, with a median target price of $41.00. In analyzing these forecasts, the average price target given by analysts for Pfizer Inc. (PFE) is $43.81.
